» Articles » PMID: 29110146

Atherosclerosis, Periodontal Disease, and Treatment with Resolvins

Overview
Publisher Springer
Date 2017 Nov 8
PMID 29110146
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: This review aims to discuss the existing evidence on the link between atherosclerosis and periodontitis by particularly presenting new findings that link the pathology and therapy of these diseases. Acute vascular ischemic events that can lead to stroke or myocardial infarction are initiated by inflammatory processes leading to rupture or erosion of plaques susceptible to thrombosis ("high risk" or "vulnerable"). These are highly inflamed plaques residing in the media and adventitia that may not be detected by angiography measurments of luminal narrowing. Statistically significant excess risk for atherosclerotic cardiovascular disease has been reported in persons with periodontitis independent of established risk factors. We hypothesized that the systemic pathologic links also represent potential therapeutic links.

Recent Findings: We recently demonstrated that periodontal inflammation promotes atherosclerotic plaque inflammation and destabilization. As discrete pathological regions, these plaques with a high susceptibility to rupture can be imaged and differentiated from lower risk plaques. In cholesterol-fed rabbits with periodontal disease, circulating inflammatory mediators were also significantly elevated thereby contributing to "vulnerable blood," a systemic characteristic of high risk for cardiovascular events. New studies show that certain lipid mediators, including lipoxins and resolvins, are potent in preventing and possibly treating a number of inflammation-associated diseases, including periodontitis and vascular inflammation. The concept of the vulnerable patient and the pro-resolving approach open new terrain for discovery of paradigm-changing therapies for the prevention and treatment of two of the most common diseases of man. Importantly, lipoxins and resolvins are natural receptor agonists that do not exhibit the same pro-atherogenic side effects attributed to anti-inflammatory medications (e.g., NSAIDs) but rather coordinate resolution of inflammation and a return to homeostasis.

Citing Articles

The Application of Resolvin D1-Loaded Gelatin Methacrylate in a Rat Periodontitis Model.

Xing Z, Liu J, Cai J, Jiang X, Liang J, Fujio M Pharmaceutics. 2025; 17(1).

PMID: 39861667 PMC: 11768520. DOI: 10.3390/pharmaceutics17010016.


The Molecular Comorbidity Network of Periodontal Disease.

Martinez-Garcia M, Hernandez-Lemus E Int J Mol Sci. 2024; 25(18).

PMID: 39337647 PMC: 11432284. DOI: 10.3390/ijms251810161.


Omega-3 polyunsaturated fatty acids and pulmonary arterial hypertension: Insights and perspectives.

Massaro M, Quarta S, Calabriso N, Carluccio M, Scoditti E, Mancuso P Eur J Clin Invest. 2024; 54(11):e14277.

PMID: 38940236 PMC: 11490397. DOI: 10.1111/eci.14277.


Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.

Fredman G, Serhan C Nat Rev Cardiol. 2024; 21(11):808-823.

PMID: 38216693 DOI: 10.1038/s41569-023-00984-x.


Association of periodontitis and tooth loss with extent of coronary atherosclerosis in patients with type 2 diabetes mellitus.

Shen M, Li Z, Li H, Yan X, Feng B, Xu L Front Endocrinol (Lausanne). 2023; 14:1243992.

PMID: 38075042 PMC: 10702216. DOI: 10.3389/fendo.2023.1243992.


References
1.
Granada J, Kaluza G, Wilensky R, Biedermann B, Schwartz R, Falk E . Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention. 2009; 5(1):140-8. DOI: 10.4244/eijv5i1a22. View

2.
Myerburg R, Interian Jr A, Mitrani R, Kessler K, Castellanos A . Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997; 80(5B):10F-19F. DOI: 10.1016/s0002-9149(97)00477-3. View

3.
Naghavi M, Libby P, Falk E, Casscells S, Litovsky S, Rumberger J . From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108(14):1664-72. DOI: 10.1161/01.CIR.0000087480.94275.97. View

4.
Chiang N, Fredman G, Backhed F, Oh S, Vickery T, Schmidt B . Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012; 484(7395):524-8. PMC: 3340015. DOI: 10.1038/nature11042. View

5.
Abela G, Picon P, Friedl S, Gebara O, Miyamoto A, Federman M . Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation. 1995; 91(3):776-84. DOI: 10.1161/01.cir.91.3.776. View